-- Redhill Gains Most in 7 Months on RHB-102 Clinical Trial Success
-- B y   D a v i d   W a i n e r
-- 2012-04-17T07:55:22Z
-- http://www.bloomberg.com/news/2012-04-17/redhill-gains-most-in-7-months-on-rhb-102-clinical-trial-success.html
Redhill Biopharma Ltd. (RDHL)  surged the
most in almost seven months after the Israeli pharmaceutical
company said a clinical trial of its RHB-102 drug against nausea
and vomiting in cancer treatments was successful.  The  shares  jumped as much as 22 percent, the biggest
intraday increase since September 2011, and were 16 percent up
at 2.50 shekels as of 10:38 a.m. in  Tel Aviv , giving the company
a market value of 131 million shekels ($35 million).  To contact the reporter on this story:
David Wainer in Tel Aviv at 
 dwainer3@bloomberg.net   To contact the editor responsible for this story:
Calev Ben-David at 
 cbendavid@bloomberg.net  